All In Biotech

Drug Trial Radar · NCT04585958

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

A Phase I Study of DS-8201a in Combination With Olaparib in HER2-Expressing Malignancies

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

May 21, 2021

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
NIH
First posted
Oct 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial identifies the side effects and best dose of DS-8201a and olaparib in treating patients with HER2-expressing cancers that have spread to other places in the body or cannot be removed by surgery or ovarian cancer that remains despite treatment with a platinum treatment (platinum resistant). DS-8201a is an antibody-drug conjugate. This agent has two components: an antibody component and a chemotherapy component. The antibody component is attached to the chemotherapy molecules. Upon administration of DS-8201a, the antibody targets and binds to tumor cells that have abundant HER2 (human-epidermal growth factor receptor 2), which is a protein on the surface of some tumor cells. The chemotherapy then enters the cells and blocks deoxyribonucleic acid (DNA) replication in the tumor cells with abundant HER2, causing them to die. Olaparib is a drug that blocks an enzyme involved in many cell functions, including the repair of DNA damage. Blocking this enzyme may help keep tumor cells from repairing their damaged DNA, causing them to die. Giving DS-8201a and olaparib may shrink or stabilize the cancer.

Conditions

  • Metastatic Malignant Solid Neoplasm
  • Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma
  • Unresectable Malignant Solid Neoplasm

Interventions

  • Biopsy ProcedureProcedure

    Undergo biopsy

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • Computed TomographyProcedure

    Undergo CT

  • Echocardiography TestProcedure

    Undergo echocardiography

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • OlaparibDrug

    Given PO

  • Trastuzumab DeruxtecanBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose/recommended phase 2 doseTime frame: Up to 42 days
  2. Incidence of adverse eventsTime frame: Up to 30 days post treatment

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona · Active not recruiting

  • UM Sylvester Comprehensive Cancer Center at Coral Gables

    Coral Gables, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach

    Deerfield Beach, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Doral

    Doral, Florida · Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Florida · Recruiting

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Kendall

    Miami, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Plantation

    Plantation, Florida · Recruiting

  • Emory University Hospital Midtown

    Atlanta, Georgia · Recruiting

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Mayo Clinic in Rochester

    Rochester, Minnesota · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.